Intervention fidelity and process outcomes of medication reviews including post‐discharge follow‐up in older hospitalized patients: Process evaluation of the MedBridge trial

What is known and objective Drug‐related problems (DRPs) are a growing healthcare burden worldwide. In an ongoing cluster‐randomized controlled trial in Sweden (MedBridge), comprehensive medication reviews (CMRs) including post‐discharge follow‐up have been conducted in older hospitalized patients t...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical pharmacy and therapeutics Vol. 45; no. 5; pp. 1021 - 1029
Main Authors Kempen, Thomas G. H., Cam, Henrik, Kälvemark, Amanda, Lindner, Karl‐Johan, Melhus, Håkan, Nielsen, Elisabet I., Sulku, Johanna, Gillespie, Ulrika
Format Journal Article
LanguageEnglish
Published England Hindawi Limited 01.10.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:What is known and objective Drug‐related problems (DRPs) are a growing healthcare burden worldwide. In an ongoing cluster‐randomized controlled trial in Sweden (MedBridge), comprehensive medication reviews (CMRs) including post‐discharge follow‐up have been conducted in older hospitalized patients to prevent and solve DRPs. As part of a process evaluation of the MedBridge trial, this study aimed to assess the intervention fidelity and process outcomes of the trial's interventions. Methods For intervention delivery, the percentage of patients that received intervention components was calculated per study group. Process outcomes, measured in about one‐third of all intervention patients, included the following: the number of identified medication discrepancies, DRPs and recommendations to solve DRPs, correction rate of discrepancies, and implementation rate of recommendations. Results and discussion The MedBridge trial included 2637 patients (mean age: 81 years). The percentage of intervention patients (n = 1745) that received the intended intervention components was 94%‐98% during admission, and 40%‐81% upon and after discharge. The percentage of control patients (n = 892) that received at least one unintended intervention component was 15%. On average, 1.1 discrepancies and 2.0 DRPs were identified in 652 intervention patients. The correction and implementation rates were 79% and 73%, respectively. Stop medication was the most frequently implemented recommendation (n = 293) and 77% of the patients had at least one corrected discrepancy or implemented recommendation. What is new and conclusion The intervention fidelity within the MedBridge trial was high for CMRs during hospital stay and lower for intervention components upon and after discharge. The high prevalence of corrected discrepancies and implemented recommendations may explain potential effects of CMRs in the MedBridge trial. In 652 patients aged 65 years or older who received a comprehensive medication review during hospital stay, on average 1.1 medication discrepancies and 2.0 drug‐related problems were found. The correction rate of discrepancies was 79% and 73% of the recommendations to solve drug‐related problems were implemented. Stop medication was the most frequently implemented recommendation and 77% of the patients had at least one corrected discrepancy or implemented recommendation.
Bibliography:Funding information
The MedBridge trial project has received governmental research funding from the Uppsala‐Örebro Regional Research Council (grant numbers RFR‐555601, RFR‐641791, RFR‐735911); Region Uppsala (grant numbers LUL‐527721, LUL‐614061, LUL‐716201, LUL‐821261); Region Gävleborg (grant numbers CFUG‐658451, CFUG‐698771); and Region Västmanland (grant numbers LTV‐675921, LTV‐712341, LTV‐736641, LTV‐840112). The project has also received funding from the Swedish Pharmacists Association (Sveriges Farmaceuter; grant number not applicable); the Thuréus Fund for Geriatric Research (Thuréus stiftelse för främjande av geriatrisk forskning; grant number not applicable); the Geriatric Fund (Geriatriska fonden; grant number not applicable); and the Swedish Heart and Lung Association (Riksförbundet HjärtLung; grant numbers FA 2017:38, FA 2018:43). No sponsor had any involvement in the study design, in the collection, analysis or interpretation of data, in the writing of the report, or in the decision to submit the article for publication.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
ISSN:0269-4727
1365-2710
1365-2710
DOI:10.1111/jcpt.13128